One sentence summary: Contact-dependent growth inhibition (CDI) is a competition mechanism recently reported in pathogenic microorganisms via delivering toxin protein(s) to inhibit neighboring bacteria, and CDI was firstly reported in probiotic E. coli Nissle 1917.
INTRODUCTION
Various mechanisms mediate cooperation and competition within a bacterial community (Nadell, Bassler and Levin 2008; Ng and Bassler 2009) . Recently, a cell-to-cell contact mode, contactdependent growth inhibition (CDI), was identified in bacteria. CDI was first described in Escherichia coli EC93 and had been demonstrated in many bacteria such as Yersinia pestis CO92, Dickeya dadantii 3937, Burkholderia pseudomallei and Xenorhabdus (Aoki et al. 2005 (Aoki et al. , 2010 Anderson, Garcia and Cotter 2012; Ogier et al. 2016) . The E. coli-type CDI system is composed of three genes, cdiB, cdiA and cdiI. CdiB, which has high homology among E. coli bacteria, is a predicted β-barrel protein that resides in the bacterial outer membrane and is required for export of CdiA to interact with neighboring target bacteria. CdiA generally includes conserved N-terminus and variable C-terminus (CdiA-CT). The distinct inhibition activity of CDI relies on the CdiA-CT, while the N-terminal domain contains hemagglutinin repeat regions predicted to a filamentous β-helical structure (Kajava et al. 2001; Aoki et al. 2008) . CdiI, which is downstream of cdiA, encodes an immunity protein that binds and inactivates CdiA-CT to protect host from auto-inhibition (Aoki et al. 2010) . CdiA-CT region in E. coli-type CDI has a conserved active VENN peptide motif, while the CDI-conserved active motif in Burkholderia-type is NxxLYN. The Burkholderia-type CDI system also contains an additional bcpO besides bcpA, bcpI and bcpB. bcpO encodes a TpsB family member that is required for the function of BcpA protein (the TpsA family member) (Anderson, Garcia and Cotter 2012) . Moreover, Pfam PF04740 proteins from Gram-positive bacteria are similar to CdiA and share C-terminal toxin domains (Holberger et al. 2012) . To date, CdiA-CT toxins have been found to exhibit a number of distinct activities. For example, E. coli EC93-mediated CDI decreases respiration and ATP levels of cells by dissipating proton gradients, suggesting that the toxin forms pores in the inner membrane of target cells. Furthermore, CdiA-CT from E. coli EC536 is tRNA anticodon nuclease that cleaves tRNA molecules, CdiA-CT of E. coli EC869 is a Zn 2+ -dependent DNase, and CdiA-CT II from D. dadantii 3937 is an Mg 2+ -dependent DNase that can degrade target-cell genomic DNA (Aoki et al. 2009 (Aoki et al. , 2010 Morse et al. 2012) .
Besides the classical cdiBAI operon, fragmentary gene pairs resembling cdiA-CT/cdiI module that encodes the VENN peptide motif and corresponding CdiI immunity protein also present in many bacteria. These fragmentary gene pairs were termed 'orphan modules' (Poole et al. 2011) . Moreover, some orphan modules retain varying length sequences in the upstream of the cdiA-CT (VENN-encoding region), while these sequences are absent in some cases (Poole et al. 2011) . Furthermore, these orphan cdiA-CT/cdiI modules usually include some sequences that are homologous to transposases and integrases. Thus, bacteria may displace the original cdiA-CT/cdiI modules with new modules by homologous recombination in the N-terminus of CdiA or through horizontal gene transfer (Beck et al. 2014b) . Thus, these orphan modules can become a reservoir of toxin delivery that provides a growth advantage in bacteria competition (Poole et al. 2011) .
Escherichia coli Nissle 1917 (EcN), isolated in 1917 by Alfred Nissle, is of serotype O6:K5:H1 and has been licensed as a medicine for treatment of gastrointestinal diseases for many years (Grozdanov et al. 2004; Sonnenborn and Schulze 2009; Losurdo et al. 2015) . Gastrointestinal probiotic EcN has many characteristics compared with other intestinal E. coli. EcN not only does not produce recognized E. coli exotoxins, but also is a serum sensitive bacterium because of a point mutation in the O-antigen polymerase wzy gene leading to the expression of a semi-rough type of O6 lipopolysaccharide (Grozdanov et al. 2002; Reister et al. 2014) . Additionally, EcN is capable of producing antimicrobial agents such as iron uptake systems, adhesions and microcins that allow EcN to outgrow and compete with pathogens (Reister et al. 2014; Mohsina et al. 2015) . Since 2012, our research group has been using EcN as a heterologous host for expression of small-molecule compounds luminmycins and glidobactins, as a tumor-targeting strain harboring antitumor protein (Azurin) for the inhibition of tumor growth, and our investigations on maturation mechanism and structure of genotoxin colibactin in EcN have been reported (Bian et al. , 2013 (Bian et al. , 2015 Fu et al. 2012; Zhang et al. 2012) . Herein, we identified two cdi operons, an intact CDI system and an 'orphan' cdiA-CT/cdiI module, located in different loci of the genome of EcN by genome scanning. Both CdiA-CTs in the E. coli DH5α showed auto-inhibition activity after induction expression, and CdiI was immunity protein and inactivated toxin protein CdiA. In addition, we obtained the most potent mutant of toxin CdiA via sequential deletion of single amino acid residue one by one. Therefore, this study demonstrated that the CDI system was firstly characterized in probiotic EcN, and a novel competition mechanism mediated by the CDI system might presumably play an important role in special growth competition for EcN. In addition, the orphan module might be a toxic reservoir and have bioactivity via transposition and homologous recombination. Above all, the CDI system is prevalent between pathogens and probiotic and may provide a new mechanism for EcN in treating intestinal pathogens, as well some potential novel competition mechanisms in EcN will be exploited.
MATERIAL AND METHODS

Bacterial strains, plasmids and cultivation conditions
Escherichia coli were grown in Luria-Bertani (LB) broth supplemented with antibiotics at the following concentrations: ampicillin (amp) 50 μg ml −1 ; chloramphenicol (cm) 10 μg ml −1 ; tetracycline (tet) 10 μg ml −1 ; E. coli were grown in LB agar supplemented with antibiotics: ampicillin (amp) 100 μg ml −1 ; chloramphenicol (cm) 15 μg ml −1 . Cultures were incubated at 37
• C for E. coli and 30
• C for EcN/pSC101-ccdA-gbaA . The plasmids and strains are listed in Table S1 (Supporting Information).
Construction of CdiA-CT EcN and deletion mutants
CdiA-CTs (183 amino acids) of EcN were amplified using primer pair cdiA-CT-S/cdiA-CT-A and cloned into vector pBAD24 by one step of linear plus linear homologous recombination (LLHR) ( (Table S2 , Supporting Information). All plasmids were harbored in E. coli DH5α cells.
Construction of CdiA-CT and its truncated mutants together with CdiI
CdiA-CT/cdiI, cdiA-KO4/cdiI, cdiA-KO8/cdiI and cdiA-KO9/cdiI fragments were amplified using four primer pairs (CdiA-CT-S/CdiAI-A, CdiA-CTKO4-S/CdiAI-A, CdiA-CTKO8-S/CdiAI-A and CdiA-CTKO9-S/CdiAI-A) and were then cloned into the pBAD24 achieving the pBAD-CT/cdiI, pBAD-KO4/cdiI, pBAD-KO8/cdiI and pBAD-KO9/cdiI by LLHR (Fig. S1A , Supporting Information) (Fu et al. 2012) , respectively. The above plasmids were transformed in E. coli DH5α. Escherichia coli DH5α harboring co-expression constructs grown overnight at 37
• C in LB with amp antibiotics.
Construction of CdiA-KO8 together with CdiB and CdiI
RhaB-cm product amplified by fusion PCR and linear vector pBAD-KO8 acquired by Xba I digestion were co-transformed into GB05-dir yielding construct pBAD-KO8-RhaB-cm by LLHR (Fig. S1A, Supporting Information) . Then, cdiB and cdiI genes were introduced into the plasmid pBAD-KO8-RhaB-cm separately under the control of inducible rhamnose promoter by RecET recombineering yielding constructs pBAD-KO8-RhaB-cdiB and pBAD-KO8-RhaB-cdiI. Meanwhile, cdiB as well as cdiI was cloned into the plasmid pBAD-KO8-RhaB-cm under the control of rhamnose promoter yielding pBAD-KO8-RhaB-cdiB/cdiI. CdiA-KO8 fragment was under the control of arabinose promoter. All plasmids were transformed in E. coli DH5α.
The inhibition bioassay of E. coli cells harboring constructs
The constructs of pBAD-CT, pBAD-CT O1 and deletions of CdiA-CT (pBAD-KO4, pBAD-KO5, pBAD-KO6, pBAD-KO7, pBAD-KO8, pBAD-KO9, pBAD-KO10, pBAD-KO11, pBAD-KO12, pBAD-KO16 and pBAD-KO26) were separately transformed into E. coli DH5α cells and were selected on LB with amp antibiotic. Transformants were grown overnight at 37
• C in LB with amp on a rotary shaker. Overnight culture was adjusted to OD 600 0.05 and then the fresh culture was cultivated at 37
• C, 200 rpm, separately, and 0.15% L-arabinose was added to culture after 1 h 30 min incubation (OD 600 ≈ 0.15-0.25). Culture was incubated at 37
200 rpm with shaking and OD 600 was measured over time. The bioassay of the constructs (pBAD-CT/cdiI, pBAD-KO4/cdiI, pBAD-KO8/cdiI and pBAD-KO9/cdiI) and different co-expression constructs (pBAD-KO8-RhaB-cm, pBAD-KO8-RhaB-cdiB, pBAD-KO8-RhaB-cdiI and pBAD-KO8-RhaB-cdiB/cdiI) was the same as the above procedure. Meanwhile, every construct is presented as three independent experiments. Constructs (pBAD24, pBAD-KO4, pBAD-KO5, pBAD-KO6, pBAD-KO7, pBAD-KO8, pBAD-KO9, pBAD-KO10, pBAD-KO11, pBAD-KO12, pBAD-KO16 and pBAD-KO26) were grown overnight at 37
• C in liquid LB with amp antibiotic. Overnight culture was adjusted OD 600 0.05 using fresh culture and then fresh culture was cultured until the OD 600 reached 0.15-0.25. Afterwards, the culture was separately diluted and plated in LB with amp or LB with amp and L-arabinose. The plates were incubated at 37
• C for 16 h and then a colony-forming units (CFU) assay was conducted. The CFU assay of the constructs (pBAD-CT/cdiI, pBAD-KO4/cdiI, pBAD-KO8/cdiI and pBAD-KO9/cdiI) was the same as above. Different co-expression constructs were grown overnight at 37
• C in LB with amp and cm antibiotics until the OD 600 reaching 0.15-0.25. Afterwards, culture was separately diluted and plated in LB with amp and cm; or LB with amp, cm and 0.15% L-arabinose; or LB with amp, cm, 0.15% L-arabinose and 0.15% rhamnose. The plates were incubated at 37
• C for 16 h and a CFU assay was conducted. The above constructs are presented as three independent experiments.
RESULTS
Bioinformatics analysis of CDI system-encoding loci in EcN genome
The analysis of EcN genome revealed that the characteristic features of CDIs at two loci ( Fig. 1 (Fig. S2, Supporting Information) . Therefore, both CdiA-CTs had the same function based on the 100% homolog of both CdiI. In addition, examination of CDI demonstrated that the orphan cdiA-CT/cdiI pairs were quite common in other bacteria, and the typical orphan cdiA-CT fragments were followed by small ORFs predicating CdiI immunity proteins. The orphan module of EcN was far away from the intact system and was different with other E. coli bacteria such as E. coli EC93, but similar to Dickeya dadantii 3937 and Yersinia pestis CO92. Additionally, two transposable elements settled downstream of potential immunity proteins in both loci, respectively, and their GC-content decreased abruptly compared to cdi operons. Therefore, we speculated that cdiA-CT/cdiI modules were unstable and might be transferred by transposition.
Both CdiA-CTs are active inhibitory toxins
The C-terminal of CdiA generally is the inhibitory activity region. Due to the low similarity of CdiA-CT between EcN and other E. coli, we attempted to test its inhibitory activity by transferring into a heterologous host. We cloned cdiA-CT and cdiA-CT O1 into pBAD24 in which they were under the control of arabinoseinducible promoters. The constructs were then transferred into did not increase after L-arabinose induction for 3 h, while the E. coli DH5α cells harboring empty vector grew normally (Fig. 2) . The highest OD 600 of E. coli/pBAD-CT was 1.2 and lower than E. coli/pBAD-CT O1 that OD 600 was 1.3. This result demonstrated that the induced expression of both CdiA-CTs inhibited the growth of E. coli DH5α cells and both CdiA-CT proteins were functional toxins. Although CdiA-CT and CdiA-CT O1 had one different amino acid residue (A vs D) (Fig. 2) , their inhibitory activity was similar, suggesting that this discrepant amid acid was not critical for inhibitory activity.
Sequential deletion of amino acid residues determine the most potent CdiA-CT
The highest active region of CdiA-CT was determined by deletion analysis. A series of deletion mutants were constructed all of which were under the control of arabinose-inducible promoter for bioactivity test. The growth of E. coli harboring construct pBAD-KO4, which was deletion of four amino acids (VENN), was inhibited at 4 h after the addition of L-arabinose inducer and the OD 600 was 0.48 at 4 h, after that the OD 600 began to decline. The inhibitory activity of E. coli containing construct pBAD-KO4 was stronger than E. coli/pBAD-CT. Removal of N-terminal-conserved VENN motif of CdiA-CT (pBAD-KO4) enhanced growth inhibitory activity as previously shown by Aoki group (Aoki et al. 2010) . The growth of E. coli/pBAD-KO8, which was deletion of 8 amino acid residues (VENNSLSA), was directly inhibited after addition of L-arabinose and the highest OD 600 was 0.31 at 4 h. However, the growth of E. coli/pBAD-KO12 was similar to E. coli/pBAD-KO4 and the highest OD 600 was 0.51 at 2 h. The OD 600 of E. coli/pBAD-KO16 reached 2.3 at 6 h. However, the growth of E. coli/pBAD-KO26 was normal and OD 600 could reach 3.1. Meanwhile, the CFU assay was concordant with the bioassay of E. coli cells. Mutant pBAD-KO8 had a significant inhibitory activity and was more active than other mutants (pBAD-KO4, pBAD-KO12 and pBAD-KO16). In addition, deletion construct of 12 amino acid residues had similar inhibitory activity to construct pBAD-KO4. Deletion of 26 amino acid residues (pBAD-KO26) abolished growth inhibitory activity (Fig. 3A, B and D) . In addition, to determine the number of amino acids necessary for functional activity, we constructed 5-(VENNS), 6-(VENNSL), 7-(VENNSLS), 9-(VENNSLSAG), 10-(VENNSLSAGW), 11-(VENNSLSAGWN) amino acid deletions of N-terminus of CdiA-CT yielding pBAD-KO5, pBAD-KO6, pBAD-KO7, pBAD-KO9, pBAD-KO10 and pBAD-KO11. The bioassay of E. coli harboring different constructs demonstrated that pBAD-KO4, pBAD-KO10 and pBAD-KO12 had similar inhibitory activity. The construct pBAD-KO5 had slightly strong activity compared to pBAD-KO7. The constructs pBAD-KO6 and pBAD-KO11 had weak inhibitory activity similar to above pBAD-CT. The constructs pBAD-KO8 and pBAD-KO9 had the most strongly inhibitory activity to the host. In addition, the protein expression levels of the different truncation constructs in E. coli DH5α or E. coli BL21 cells were different (Fig. S5, S6 and S7, Supporting Information). The expression of protein CdiA-CT was detected obviously by SDS-PAGE, but the expression of other proteins might be low and could not be detected (Fig. S5 and S6, Supporting Information) . However, the inhibition activity of CdiA-CT was lower than other truncation constructs including KO4, KO5, KO7, KO8, KO9, KO10, KO11 and KO12. Thus, we speculated that the deletions of protein CdiA improved bioactivity via affecting the active core site of CdiA-CT that easily combined with the target region, but not via improving the protein product (Fig. S4, Supporting Information) . In addition, the amino acids of position 8 (A) and position 9 (G) starting from VENN sequence did not affect the most core active site of C-terminus of protein CdiA. This data also confirmed that CdiA-CT and CdiA-CT O1 had the similar auto-inhibition activities. Thus, the bioassay and CFU assay demonstrated that the removal of 8 or 9 residues at the N-terminal of CdiA-CT could significantly improve bioactivity (Fig. 3C and D and Fig. S3 , Supporting Information).
CdiI neutralizes the toxicity of CdiA-CT and truncation constructs
CdiI immunity protein generally lies downstream of CdiA and protects cells from CdiA inhibition. A non-annotated ORF in the intact cdi gene cluster of EcN was deduced to be a CdiI immunity protein. Therefore, we cloned cdiA-CT/cdiI (pBAD-CT/cdiI) as well as cdiA-KO4/cdiI (pBAD-KO4/cdiI), cdiA-KO8/cdiI (pBAD-KO8/cdiI) and cdiA-KO9/cdiI (pBAD-KO9/cdiI) fragments under the control of arabinose promoter. These constructs were transformed into E. coli DH5α cells. Bioassay of E. coli DH5α cells showed that E. coli/pBAD-CT/cdiI (OD 600 ≈ 2.0) outgrew E. coli/pBAD-CT (OD 600 ≈ 1.1) after addition of L-arabinose inducer. After addition of inducer, the OD 600 of E. coli/pBAD-KO4/cdiI was 1.2, which exceeded OD 600 of E. coli/pBAD-KO4. Meanwhile, the OD 600 of E. coli/pBAD-KO8/cdiI could reach 0.5, but OD 600 of E. coli/pBAD-KO8 was only 0.3 at 8 h. The OD 600 of E. coli/pBAD-KO9 was only 0.27 but the OD 600 of E. coli/pBAD-KO9/cdiI was 0.6 at 8 h (Fig. 4A) . Above results showed that cdiI gene could recover the growths of E. coli harboring different truncation constructs to a certain degree. However, CdiI protein could neutralize the inhibitory activity of CdiA-CT well, but could not totally recover the inhibitory activity of truncation constructs (CdiA-KO4, CdiA-KO8 and CdiA-KO9) within 8 h. However, the CFU assay showed that CdiI could neutralize the inhibitory activity of truncation constructs (Fig. 4B) . Therefore, the bioassay and CFU assay demonstrated that CdiI was an immunity protein and neutralized bioactivity of CdiA.
As previously mentioned, the CDI operon consists of cdiB, cdiA and cdiI genes and our studies showed that CdiI protein was immunity protein. Next, we determine whether CdiB protein directly participated in inhibiting bioactivity of CdiA protein in heterologous host. Based on the bioinformatics results, CdiB of EcN was shorter than the proteins CdiB of other E. coli because gene cdiB had a stop codon that produced truncated CdiB pro- tein. We speculated that the stop codon might affect function of CdiB. Then, this point mutation (A base) of CdiB was successfully repaired via recombineering using ccdB for counter-selection. Then, we cloned repair cdiB, cdiI and repair cdiB/cdiI genes, which were under the control of rhamnose-inducible promoters, in the plasmid pBAD-KO8, respectively, yielding pBAD-KO8-RhaB-cdiB, pBAD-KO8-RhaB-cdiI and pBAD-KO8-RhaB-cdiB/cdiI constructs, respectively, and they were transformed into E. coli DH5α cells as well. Bioassay of these E. coli DH5α cells demonstrated that the growth of E. coli DH5α harboring pBAD-KO8-RhaB-cdiB was similar to the growth of E. coli DH5α harboring pBAD-KO8-RhaB-cm after addition of L-arabinose and L-Rhamonse inducers. However, the growth of E. coli DH5α/pBAD-KO8-RhaB-cdiI was normal and was similar to the host with CdiB and CdiI protein.
Meanwhile, the OD 600 of E. coli harboring CdiI protein was 1.9, while the OD 600 of E. coli harboring co-expression protein of CdiB and CdiI was 2.1 (Fig. 5A) . The CFU assay showed that CdiB protein could not inhibit the toxic effect caused by the production of CdiA toxin regardless of the addition of L-rhamnose in heterologous host E. coli. However, the CdiI protein could suppress the toxin solely even in the absence of L-rhamnose inducer. Coexpression protein encoded by cdiB and cdiI genes also neutralized the toxin. Meanwhile, CdiB slightly contributed to neutralize the inhibitory activity when cdiB was co-expressed with cdiI (Fig. 5B) . Thus, we speculated that CdiI was an immunity protein that could neutralize the toxin in the same host; however, repaired CdiB could not directly participate in inhibiting toxin in the heterologous host in this work because the CdiB was transporter. We speculated that CdiB might be interaction with conserved N-terminal CdiA directly, which need to be studied next.
DISCUSSION
In this study, we identified two CDI systems in the intestinal probiotic E. coli Nissle 1917 and had the common characteristics found in the E. coli-type CDI systems. The CDI system reported by Aoki et al. (2005) had a unique mechanism for inter-bacterial communication and was capable of modulating bacterial own population densities by affecting bacterial communities. CDI systems allow bacteria produce toxin proteins CdiA to inhibit the growth of neighboring target cells upon direct cell-to-cell contact (Slechta and Mulvey 2006) . However, the mechanism by which these CDI systems are deployed in the environment and precise function they provide remains unclear. Universally, CdiA proteins have N-and C-terminal regions and the growth inhibitory activity is contained within the CdiA-CT region. In addition, CdiA proteins carry a variety of sequence-diverse C-terminal domains representing a collection of distinct toxins (Beck et al. 2014a) . In this study, we demonstrated that CdiA-CTs had low homology among bacteria E. coli, and might have distinct toxins. Moreover, CdiA-CT and CdiA-CT O1 included toxic domain and had similar inhibitory activity even though both had a discrepant amino acid. Therefore, the discrepant amino acid is not located at essential active domain; however, the greater inhibitory activity was always shorter than CdiA-CT region. At 2010, Aoki group demonstrated the highest active region of CdiA-CT of EC93 was removal of 45 residues from N terminus, which included N-terminus (41 amino acid residues) and the conserved VENN motif (four amino acid residues) (Aoki et al. 2010) . In this work, we deleted the four residues (VENN) enhanced the bioactivity of CdiA-CT, which was the same with the result of Aoki group. In addition, sequential deletion of amino acids demonstrated that the most potent region of CdiA-CT of EcN had deletion of eight residues or nine residues beginning from N-terminal VENN motif of CdiA, and on the contrary the VENN motif weakened the inhibitory activity of CdiA-CT protein. CdiA-CT truncation constructs expressed in E. coli cells were toxic except with removal of 26 amino acids from N-terminus of CdiA-CT. The conserved motif among CdiA of E. coli impaired the toxin activity, but they might be important for homologous recombination in order to acquire new cdiA-CT/cdiI and participate in the variability of secreted toxins (Mercy et al. 2016) . Immunity protein CdiI could provide immunity to cells. In this study, CdiI protein abolished the toxic activity of CdiA-CT in the host E. coli DH5α cells. However, CdiI could not completely recover the growth of hosts containing other constructs in short time. Highly homologous CdiB was a predicted transporter protein in CDI system; however, in this study we found that repaired CdiB might not directly participate in inhibiting toxin activity in heterologous host E. coli DH5α. The peptide transporter CdiB might be interaction with N-terminal of CdiA because CdiB and CdiA-NT had high homology among E. coli. To the best of our knowledge, this is the first study that examines the relationship between CdiB and CdiA in the heterologous host. In addition, sequences of CdiA-CT and CdiI from EcN had low homology compared to other E. coli cells. Thus, CdiA-CT of EcN not only riches toxic diversity in present, but also maybe have inhibitory bioactivity via a novel unknown mechanism. In addition, the cognate toxin/immunity pairs closely linked indicating that they presumably co-evolved as a unit. Furthermore, diversity of cdiA-CT/cdiI sequences has been shown and many novel activities have been characterized, and have practical applications in biotechnology and nucleic acid research (Ruhe, Low and Hayes 2013) .
CDI systems have an unusual genetic organization and often contain fragmentary gene pairs that resemble cdiA-CT/cdiI toxin/immunity modules at downstream of cdiBAI gene cluster, such as E. coli EC93 and E. coli EC869 (Poole et al. 2011) . We demonstrated that an orphan cdiA-CT/cdiI module exists farther from the CDI system on the other locus on the EcN chromosome, as well as CdiA-CT O1 has inhibitory activity. Indeed, the orphan CdiA-CT/cdiI gene pairs often shared conserved sequences with N-terminal cdiA gene and produced a functional chimera by homologous recombination . The fusion of N-terminal CdiA of EC536 with CdiA-CT of EC93 toxin region at the VENN sequence generated a functional CdiA protein. Moreover, CdiA-CT domains from Y. pestis CO92 and D. dadantii 3937 could be delivered into target cells by N-terminus of CdiA of E. coli EC536. Hence, the CdiA-CT/CdiI modules could horizontally change between bacteria by homologous recombination and the high homologous N-terminal residues indicated that transferring toxin protein took advantage of the same mechanism (Aoki et al. 2010) . However, fusion of the CdiA-CTii from Bp 1026b at the VENN motif of the E. coli EC93 CdiA protein did not produce a functional chimera ). Therefore, it was possible that specific sequences were required for CdiA-CT delivered to target cells. In this study, transposase and integrase settled downstream of both cdi operon in the chromosome of EcN; therefore, we speculate that both cdiA-CT/cdiI modules of EcN maybe change by transposition and homologous recombination.
Based on the above results, the CDI system is widespread in many pathogenic bacteria, as well as in probiotic EcN. CdiA-CT of EcN and CdiI of EcN rich the diversity of toxin proteins and immunity proteins among bacteria, but the inhibitory mechanism of CdiA-CT of EcN needs to be studied in the future. It is significant that the CDI system was firstly reported in probiotic bacterium. Moreover, EcN might outgrow with pathogenic bacteria via a novel mechanism-CDI system. This study is foundation for studying a novel competition mechanism of probiotic EcN in treating intestinal pathogenic bacteria.
